Shionogi & Co., Ltd.

2017/06/22: Shionogi to Issue of Stock Options as Compensation (Stock Acquisition Rights) to Members of Board of Directors
2017/06/12: Shionogi concluded a non-exclusive contract with PeptiDream
2017/06/07: Opioid-Induced Constipation therapeutic agent ‘Symproic® (naldemedine) Tablets 0.2mg’ launched in Japan
2017/06/02: FURTHER EVIDENCE SUPPORTS CEFIDEROCOL ACTIVITY AGAINST MDR GRAM-NEGATIVE PATHOGENS: DATA PRESENTED AT THE AMERICAN SOCIETY FOR MICROBIOLOGY MICROBE (ASM) MEETING
2017/06/01: Shionogi contributes to the second phase of the Global Health Innovative Technology Fund
2017/05/26: Attention deficit/hyperactivity disorder (AD/HD) therapeutic agent ‘INTUNIV® Tablets 1 mg/3 mg’ launched in Japan
2017/05/18: Audio Webcasting of FY2016 Financial Results
2017/05/10: FY2016 Financial Results
2017/04/25: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
2017/04/25: Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin
2017/04/24: Notice of Revisions to Dividend Forecasts
2017/04/18: Shionogi to Present New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin, and S-033188 a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
2017/04/13: Regarding the Application for Manufacture and Sales Approval of “Lisdexamfetamine Dimesylate”, a Therapeutic Agent for Attention Deficit Hyperactivity Disorder